DaVita 3Q 2026: Revenue $3.58B, Net income $222.93M, EPS $3.4— 10-Q Summary
DaVita reported Q3 2026 revenue of $3.58B, up 4.6% YoY, with net income rising 48.3% to $222.93M and EPS increasing 66.7% to $3.4. Nine-month revenue grew 5.2% to $10.55B, driven by U.S. and international dialysis operations. The company faced challenges from ACA premium tax credit expirations and China reimbursement pressures.
How this was made
The 30-second read
Why it matters
Traders can use the reported revenue, net income, and EPS figures to reassess near-term earnings power, while monitoring payer-mix and reimbursement-driven impairment risk for subsequent quarters.
Market read
A company-specific quarterly results datapoint with explicit profitability growth, plus named reimbursement and payer-mix headwinds that can influence forward estimates.
What to watch
The summary highlights ACA premium tax credit expiration and commercial mix deterioration, which could cap future revenue per treatment even if patient growth continues.
Background
The piece is a brief summary of DaVita’s 3Q 2026 10-Q, including financial highlights and selected operating updates (U.S. treatments, ACA exchange enrollment impact, and international reimbursement pressures).
Ticker impact
DaVita reported 3Q 2026 revenue of $3.58B, net income of $222.93M, and diluted EPS of $3.4 in its 10-Q summary.
Likely near-term support as investors focus on the EPS and net income jump, tempered by concerns about reimbursement-driven impairment charges and commercial mix headwinds.
The article provides concrete quarterly financial outcomes plus specific operational headwinds (ACA credit expiration, China reimbursement pressure) that can offset some of the earnings strength.
Market effects
Dialysis providers may face ongoing reimbursement and payer-mix volatility, with impairment charges signaling sensitivity to international reimbursement regimes.
U.S. dialysis treatment growth is modestly positive, while international (notably China) reimbursement pressure is a drag.
Limited spillover beyond healthcare services, unless reimbursement trends in dialysis expand across peers.
Counterpoint
The headline EPS surge may be less durable if impairment charges and reimbursement pressures (especially China) continue to rise, making the quarter potentially noisy rather than trend-setting.
Key entities
- companyDaVita Inc.
U.S.-listed dialysis provider reporting 3Q 2026 financial results and operating updates in a 10-Q summary.
